The Biomedical Informatics Shared Resource builds upon a longstanding collaboration among the Yale Center for Medical Informatics (YCMI), the YCC Clinical Research Service (CRS), and the Yale Department of Pathology Informatics Group. The Shared Resource was inaugurated in 1996 with the initial goal of developing a multi-disciplinary database to collect, store, curate, and help analyze data .for clinical trials and clinical research studies, a system now called Trial/DB. Over the past decade, the activities of the Shared Resource have significantly broadened. Trial/DB is now robustly operational and is being used for all YCC investigator initiated trials, and is continuing to be augmented and refined to meet the needs of YCC researchers. The TrialTracker system was built to track administrative informatics about trials, and is now used for all YCC trials. One major current project is developing a Cancer Data Repository (CaDR) building on the Yale Tumor Registry system. The development of the CaDR is a step toward developing a much broader institutional clinical data repository at Yale, using cancer as a pilot domain. Another initiative, in support of YCC bioscience, involves maintaining and refining two databases and related software tools, Cruella (for tissue array research) and GeneCube (for DMA microarray research). The Shared Resource is also involved in a number of activities related to the national caBIG initiative. Additional activities include 1) incrementally integrating Trial/DB, and ultimately the CaDR, with other information systems used by the YCC, and 2) coordinating YCC's activities with data-intensive genomic/proteomic informatics and clinical imaging infrastructure being developed at Yale. Overall usage of this facility by Cancer Center members is 94.6% (88.8% Peer-reviewed). The Shared Resource is utilized by 17 YCC users, based in 7 of the 8 YCC programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-30
Application #
7673440
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-08-01
Budget End
2009-07-31
Support Year
30
Fiscal Year
2008
Total Cost
$178,812
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Kelada, Olivia J; Decker, Roy H; Nath, Sameer K et al. (2018) High Single Doses of Radiation May Induce Elevated Levels of Hypoxia in Early-Stage Non-Small Cell Lung Cancer Tumors. Int J Radiat Oncol Biol Phys 102:174-183
Powles, Ryan L; Redmond, David; Sotiriou, Christos et al. (2018) Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol 4:e181564
Wang, Shi-Yi; Hsu, Sylvia H; Huang, Siwan et al. (2018) Regional Practice Patterns and Racial/Ethnic Differences in Intensity of End-of-Life Care. Health Serv Res 53:4291-4309
Gettinger, S N; Choi, J; Mani, N et al. (2018) A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nat Commun 9:3196
Liu, Huafeng; Li, Xin; Hu, Li et al. (2018) A crucial role of the PD-1H coinhibitory receptor in suppressing experimental asthma. Cell Mol Immunol 15:838-845
Altwerger, Gary; Bonazzoli, Elena; Bellone, Stefania et al. (2018) In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers. Mol Cancer Ther 17:1003-1011
Sanmamed, Miguel F; Chen, Lieping (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:313-326
Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083
Bellone, Stefania; Buza, Natalia; Choi, Jungmin et al. (2018) Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clin Cancer Res 24:3282-3291
Altan, Mehmet; Kidwell, Kelley M; Pelekanou, Vasiliki et al. (2018) Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer 4:40

Showing the most recent 10 out of 675 publications